Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.
You may also be interested in...
Internal US FDA Disagreements Feature In One-Quarter Of Novel Approvals
A team led by Dalhousie University researchers examined 174 novel approvals from 2011-2015 and found 155 instances of disagreement, affecting 42 drugs.
Case Studies In FDA's Regulatory Interpretation Of Clinical Trials
For more than 15 years, the Pink Sheet's Drug Review Profile series has looked closely at FDA approval documents, providing a long view of the pitfalls and pitches presented in the NEJM series on interpreting clinical trial results.
FDA Changed Course On Zontivity Because Of Skepticism Of Subgroups At High Levels
Large, complex dataset supporting Merck’s vorapaxar NDA invited “slicing and dicing” of the data by the primary reviewers – and made weight-based restrictions a key issue at the late-cycle and advisory committee meetings. But unusual, late-in-the-game reviews by high level FDA officials led to a post-panel U-turn.